← Back to Search

Procedure

Surgical Tissue Flap for Glioblastoma

N/A
Waitlist Available
Led By John Boockvar, MD
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trialassesses the safety of a surgical technique for newly diagnosed GBM patients, with the aim of improving survival.

Who is the study for?
This trial is for adults over 18 with newly diagnosed GBM who are expected to live at least 6 months and can have an MRI. They must be able to undergo a specific surgery, use birth control if of reproductive potential, sign consent, have a KPS of 70% or more, and meet certain lab criteria. Pregnant women, those already treated for GBM or with active infections or other significant health risks are excluded.
What is being tested?
The study tests the safety of using one's own tissue (TPF or pericranial flap) surgically placed into the brain after tumor removal in patients with GBM. The goal is to see if this method is safe and might help extend the time without disease progression.
What are the potential side effects?
Potential side effects may include complications from surgery such as infection, bleeding, reaction to anesthesia, and issues related to healing at both the donor site and where the tissue is placed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety parameter: proportion of patients experiencing increase in seizures, stroke, and infection
Safety parameter: proportion of patients experiencing rapidly progressive disease as indicated by MRI using RANO Criteria
Secondary study objectives
Overall Survival (OS)
Progression Free Survival (PFS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Surgical tissue autograft: TPF flap/pericranial flapExperimental Treatment1 Intervention
Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients

Find a Location

Who is running the clinical trial?

Northwell HealthLead Sponsor
474 Previous Clinical Trials
469,122 Total Patients Enrolled
16 Trials studying Glioblastoma
861 Patients Enrolled for Glioblastoma
John Boockvar, MD3.916 ReviewsPrincipal Investigator - Northwell Health
Northwell Health
13 Previous Clinical Trials
813 Total Patients Enrolled
11 Trials studying Glioblastoma
772 Patients Enrolled for Glioblastoma
5Patient Review
Dr. Boockvar is a life-saver. Quite literally. My brother was diagnosed and in surgery to treat his condition within 24 hours. His bedside manner is comforting, and he is very intelligent. We are grateful to have him in our lives.

Media Library

Surgical Tissue Flap (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03630289 — N/A
Glioblastoma Research Study Groups: Surgical tissue autograft: TPF flap/pericranial flap
Glioblastoma Clinical Trial 2023: Surgical Tissue Flap Highlights & Side Effects. Trial Name: NCT03630289 — N/A
Surgical Tissue Flap (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03630289 — N/A
~2 spots leftby Dec 2025